AstraZeneca

Phoenix, Arizona

OncologyantibodyPhase IIIListed · AZN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

3mo agoTrial registeredMar 23, 2026Source filing (opens the source filing in a new tab)

Momentum

60no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Dec 6, 2018
Non-Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: AstraZeneca · A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
ClinicalTrials.gov · NCT03800134 (opens the source filing in a new tab)
Trial
PHASE3 registered
Dec 29, 2017
Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · ACTIVE_NOT_RECRUITING · sponsor: M.D. Anderson Cancer Center · Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
ClinicalTrials.gov · NCT03391869 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 75%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
3mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Jun 2025Trial registeredSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE3 registered

PHASE3 registered